Клиническая эффективность Максаквина

1. Структура и антибактериальная активность Максаквина / / Пульмонология.— 1993.— Приложение 1.

2. Mciyer K.U., Ella l J.A . Lomefloxacin microbiologic assessment and unique properties / / Am. J. Med.— 1992.— Vol. 92, SuppM A .— P. 58S— 62S.

3. Фармакокинетические свойства Максаквина / / Пульмонология.— 1993.— Приложение 1.

4. Применение Максаквина для лечения и профилактики ин ­фекций мочевыводящих путей / / Там же.

5. Максаквин при лечении обострений хронического бронхита / / Там же.

6. . Amaya-Tapia G., Andrade-Villanueva J., Flores-Glaxiola A. et al. Safety and efficacy of lomefloxacin and cefaclor in the treatm ent of skin and skin structure infections / / Int. J. Antimicrob. Agents.— 1992.— Vol. 2.— P. 55— 60.

7. Seto W .-IL, Lau F.L., Gotuzzo E .IL , Carrillo C. Lomefloxacin versus trim cthoprim /sulfamethovazole in the treatm ent of adults with acute bacterial diarrhea / / Int. J. Antimicrob. Agents.— 1992.— Vol. 2.— P. 61— 66.

8. . Rizk E. A worldwide clinical overview of lomefloxacin, a oncedaily fluoroquinolone / / Int. J. Antimicrob. Agents.— 1992.— Vol. 2 .— P. 67— 68.

9. Gotuzzo E ., Carrillo C .t Seas C. et al. Treatm ent of severe cholera with lomefloxacin once-a-day / / Program and Abstracts of the 4th International Symposium on New Quinolones.— Munich, 1992.— P. 353.— Abstract 258.

10. Carrillo C., Tolmos J., Adachi J. et al. In vitro antimicrobial susceptibility testing of 319 toxigenic Vibrio cholerae 01, ElTor, strains isolated during the cholera outbreak in Peru, comparing with 204 isolates of Shigella sp. / / Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy.— W ashington: American Society for Microbiology, 1992.— P. 242.— Abstract 793.

11. Gentry L.O ., Koshdel A. Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatm ent of serious gram-negative infections of the skin and skin structure / / Am. J. Med.— 1989.— Vol. 87.— P. 132S— 135S.

12. Quintero-Perez N .P., A ndrade-V illanuevaJ.F ., Leon-Garnica G. et al. Efficacy and safety of intravenous ciprofloxacin in the treatm ent of serious infections. A comparison with ceftazidime / / Ibid.— Vol. 87, Suppl.5A.— P. 198— 201.

13. Parish L.C ., Asper R. Systemic treatm ent of cutaneous infections: a comparative study of ciprofloxacin and cefotaxime / / Ibid.— 1987.— Vol. 82, Suppl.4A.— P. 239— 241. ’

14. Perez- Ruvalcaba V.A., Q uintero-Perez N .P., M orales-Reyes J.J. et al. Double-blind comparison of ciprofloxacin with cefotaxime in the treatm ent of skin and skin structure infections / / Ibid.— P. 242— 246.

15. Ramirez-Ronda C .IL, Saavedra S., Rivera-Vazqucz C.R. Comparative double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections / / Ibid.— P. 220— 223.

16. Self P.L., Zelojf B .A ., Sollo D., Gentry L.O. Use of ciprofloxacin in the treatment of serious skin and skin structure infections / / Ibid.— P. 239— 241.

17. DuPont II.L ., Edelman R ., Kimmey M . Infectious diarrhea from E.coli to Vibrio / / Patient Care.— 1991.— P. 18— 43.

18. DuPont ILL .,Ericsson C.D., Robinson A., Johnson P.C. Current problems in antimicrobial therapy for bacterial enteric ifection / / Am. J. Med.— 1987.— Vol. 82, SuppI.4A.— P. 324— 327.

19. Bhattacharya D ., Sen G., N air G.B. et al. Multiple drug-resistant Shigella dysenteriae Type 1 and travellers’ diarrhea III. Infect. Dis.— 1986.— Vol. 154.— P. 729—730.

20. Murray B.E. Resistance of Shigella, Salmonella and other selected enteric pathogens to antimicrobial agents / / Rev. Infect. Dis.— 1986.— Vol. 8 , Suppl.2.— P. S I 72— S181.

21. RogerieF., O ttD ., Vandepitte J. e ta l. Comparison of norfloxacin and nalidixic acid for treatm ent of dysentery caused by Shigella dysenteriae Type 1 in adults / / Antimicrob. Agents Chemother.— 1986.— Vol. 28.— P. 883— 886.

22. Bose R ., Nashipuri J.N . Sen P.K. et al. Epidemic of disentery in West Bengal: clinician’s enigma / / Lancet.— 1984.— Vol. 2.— P. 1160.

23. Bennish M .E , Salam M .A ., Haider M .A ., Barza M . Therapy for shigellosis II. Randomized, double-blind comparison of ciprofloxacin and ampicillin / / J. Infect. Dis.— 1990.— Vol. 162.— P. 711— 716.

24. Goodman L.J., Trenholm e G.M., Kaplan R.L. et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults / / Arch. Intern. Med.— 1990— Vol. 150.— P. 541—546.

25. Gotuzzo E ., Oberhelman R.A., Maguina C. et al. Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim- sulfamethoxazole for acute shegellosis in adults / / Antimicrob. Agents Chemother.— 1989.— Vol. 33.— P. 1101 — 1104.

26. Imagawa Y., Tomizawa L , Takizawa Y. et al. Comparison of clinical efficacy of ciprofloxacin (C PEX , BAY 0 9867) and pipemidic acid (PPA) in the treatm ent of infectious enteritis by a double-blind method / / Kansenshogaku Zasshi.— 1988.— Vol. 62.— P. 322— 339.

27. Lolekha S., Patanachareon S., Thanangkul B., Vibulbandhitkit S. Norfloxacin versus co-trimoxazole in the treatm ent of acute bacterial diarrhea: a placebo-controlled study / / Scand. J. Infect. Dis.— 1988.— Vol. 56, Suppl.— P. 34— 35.

28. DeMol P., Mets T., Vandepitte J. et al. Treatm ent of bacillary dysentery: a comparison between enoxacin and nalidixic acid I I J. Antimicrob. Chemother.— 1987.— Vol. 19.— P. 695— 698.

29. DuPont I L L , Corrado M .L , Sabbaj J. Use of norfloxacin in the treatm ent of acute diarrheal disease / / Am. J. Med.— 1987.— Vol. 82, Suppl.6B .— P. 79— 83.

30. Ericsson C.D., Johnson P.C., DuPont I I .L et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for traveller’s diarrhea / / Ann. Intern. Med.— 1987.— Vol. 106.— P. 216— 220.

31. Pichler II.E ., Dirid I G., Stickler K., Wolf D. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea / / Am. J. Med.— 1987.— Vol. 82, Suppl.4A.— P. 329— 332.

32. Jones R.N . Fluoroquinolone (lomefloxacin) international surveillance trial: a report of 30 months of monitoring in vitro activity / / Ibid.— Vol. 92, Suppl.4A.— P. 52S—57S.

33. Felmingham D., Robbins M .J. In vitro activity of lomefloxacin and other antimicrobials against bacterial enteritis pathogens / / Diagn. Microbiol. Infect. Dis.— 1992.— Vol. 15.— P. 339— 343.

34. Butler T., Cartagenova M ., D unn D. Treatm ent of experimental Salmonella typhimurium infection in mice with lomefloxacin / / J.Antimicrob. C hemother.— 1990.— Vol. 25.— P. 629— 634.

35. Dubois J., St-Piere C. A ntibacterial activity of lomefloxacin against urinary tract, gastrointestinal tract, and respiratory tract pathogens / / Curr. Thcr. Res.— 1 9 8 9 .- Vol. 4 5 . - P. 100 0 -1 0 0 5 .

36. Segreti J., Nelson J.A ., Goodman L.J. el al. In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea / / Antimicrob. Agents Chemother.— 1989.— Vol. 3 3 .— P. 1385— 1387.

37. Doutsu Y., Inone Y., Masaki M . et al. Laboratory and clinical studies on NY-198 / / Chemotherapy (Tokyo).— 1988.— Vol. 36, Suppl.2.— P. 745— 762.

38. Leroy A ., Ilambert G., Fillasire J.-P ., Grise P. Penetration of lomefloxacin into human prostatic tissue / / Am. J. Med.— 1992.— Vol. 92, Suppl.4a.— P. 12S— 14S.

39. Klim berg L W ., Childs S.J., Madore R .J., Kl.imbc.rg S.R. A multicenter comparison of oral lomefloxacin versus parenteral cefotaxime as prophylactic agents in transurethral surgery / / Ibid.— P. 121S— 125S.

40. Kovarik J.M ., de Hond J.A .P .M ., Iloepelman I.M . et al. Intraprostatic distribution of lomefloxacin following multiple-dose administration / / Antimicrob. Agents Chemother.— 1990.— Vol. 34.— P. 2398— 2401.

41. .On A ., N ightingale C .IL , Q uintiliani R. et al. Lomefloxacin concentrations in bone after a single oral dose / / Am. J. Med.— 1992.— Vol. 92, Suppl.4Л.— P. 15S— 17S.

42. Woodworth J., F itzsimmons S. Lomefloxacin pharm acokinetics in young and elderly subjects / / Program and Abstracts of the Twenty-Ninth Intersciencc Conference on Antimicrobial Agents and C hem otherapy.— Washington: American Society for Micobiologv, 1989.— P. 316.— A bstract 1268.

43. Crom e P., Morrison P.J. Pharm acokinetics of a single oral dose of lomefloxacin in healthy elderly volunteers / / Drug Invest.— 1 9 9 1 ._ vol. 3.— P. 183— 187.

44. Schentag J.J., Goss T.F. Quinolone pharmacokinetics in the elderly / / Am. J. Med.— 1992.— Vol. 92, Suppl.4A.— P. 33S— 37S.

45. Crom P., Brucc-Jones P. Infection in the elderly: studies with lomefloxacin / / Ibid.— P. 126S— 129S.